BioSpace News Archive

NeuBase Therapeutics, Inc. announced the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 578,697 of its shares of common stock at a purchase price of $2.57 per share and associated unregistered warrants and concurrent private placement of an aggregate of 1,366,829 of its shares of common stock, at the same purchase price of $2.57 per share and associated unregistered warrants.

Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced the closing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at the public offering price of $75.00 per share.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 23 new employees.

Ionis Pharmaceuticals announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA® in infants and toddlers living with spinal muscular atrophy.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the approval of an inducement award to one new employee, Yisrael Katz, M.D. who is joining Oncternal as VP, Clinical Development.

CENTOGENE N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the voting results of the Company’s Annual General Meeting.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in June 2023.

Theralase® Technologies Inc., a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has successfully closed a non-brokered private placement offering of units.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on June 30, 2023.

Pyxis Oncology, Inc. reported that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 8,310 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 10,388 shares of Pyxis Oncology’s common stock to three newly hired employees.